Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Shashank Sama"'
Autor:
Shashank Sama, Sterling Rosqvist, Talicia Savage, Lesley Lomo, Kiera Sibbald, Alli Straubhar, Theresa L. Werner
Publikováno v:
Gynecologic Oncology Reports, Vol 53, Iss , Pp 101412- (2024)
Low grade serous ovarian cancers (LGSOC) in an advanced setting have limited systemic treatment options. In this paper we report a case of metastatic LGSOC harboring a BRAF mutation, treated with dabrafenib. We discuss the clinical, pathologic and mo
Externí odkaz:
https://doaj.org/article/4409c5afb5dc4e5bb35d4713ce930f60
Autor:
Shashank Sama, Kathleen Kerrigan, Jennifer A. Sinnott, Sonam Puri, Wallace Akerley, Benjamin Haaland, Shiven Patel
Publikováno v:
Cancer Treatment and Research Communications, Vol 35, Iss , Pp 100686- (2023)
Introduction: Limited-stage small-cell lung cancer (LS-SCLC) is potentially curable with concurrent chemoradiation (CRT). Cisplatin is the preferred platinum for the chemotherapy backbone in national guidelines. Unfortunately, many LS-SCLC patients a
Externí odkaz:
https://doaj.org/article/b8f6b57af00b42188e0b20bc2cf40fd9
Autor:
Nerea Lopetegui Lia, Abigael Luke, Syed Daniyal Asad, Shashank Sama, Leo J. Wolansky, Upendra P. Hegde
Publikováno v:
Clinical Case Reports, Vol 8, Iss 11, Pp 2148-2151 (2020)
Abstract It is important to obtain coagulation tests to assess bleeding risk in trauma patients undergoing emergency surgery when a bleeding disorder may be obscured. Identifying specific clotting factor defects is critical in successful patient mana
Externí odkaz:
https://doaj.org/article/2c95a3b40cdb4e3b9497d07dc9297f87
Autor:
Alex Hennessey, Dylan Buller, Shashank Sama, Eric Girard, Jessica Clement, Benjamin T. Ristau
Publikováno v:
Urology Case Reports, Vol 29, Iss , Pp - (2020)
Adenosquamous carcinoma is an extremely rare and lethal subtype of prostate cancer affecting an estimated 0.03 per million men annually. It has been associated with prior hormone therapy for prostate adenocarcinoma. We present a case of de novo adeno
Externí odkaz:
https://doaj.org/article/75d9032a25cd4a1191f6b00432f265df
Publikováno v:
Case Reports in Oncological Medicine, Vol 2019 (2019)
Introduction. The management of patients with advanced malignancies is challenging, although recent advances with immunotherapy have shown better outcomes. Pembrolizumab has been associated with a variety of immune-related side effects, but the occur
Externí odkaz:
https://doaj.org/article/c8acc361740844d3b1d4ea5518c0a8ad
Autor:
Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, Ignacio Garrido-Laguna
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:257-264
Background: Trifluridine/Tipiracil (TAS-102) and regorafenib are FDA-approved in the United States for treatment of refractory metastatic colorectal cancer (mCRC). FDA approvals of these agents were based on modest improvements in overall survival (O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4797adf402405a7d9fb3adb956a7846
https://doi.org/10.6004/jnccn.2022.7082
https://doi.org/10.6004/jnccn.2022.7082
Autor:
Shashank Sama, Kristen Kelley, Christos Vaklavas, Andrea Bild, Kenneth Boucher, John Lamb, Julia Lehman, Philip Moos, Theresa Werner, Adam Cohen
Publikováno v:
Cancer Research. 82:OT2-19
Background: Cytotoxic chemotherapy is the mainstay of treatment in metastatic triple negative breast cancer (TNBC), a phenotype predictive of poor survival. Similarly, ovarian cancer is the leading cause of death from gynecologic malignancies and sha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf22532595216df796fb4ddeae4b347
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-07
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-07
Autor:
Shashank Sama, Christopher Duane Nevala-Plagemann, Jarrod Smith, Lisa M. Pappas, Benjamin Haaland, Ignacio Garrido-Laguna
Publikováno v:
Journal of Clinical Oncology. 41:313-313
313 Background: Current guidelines recommend an upfront cytotoxic doublet with or without targeted therapy or immunotherapy for the management of patients with advanced gastroesophageal adenocarcinoma (aGEA).While evidence for the superiority of comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91f50ba381f1597ccf1e8cf2519c65d8
https://doi.org/10.1200/jco.2023.41.4_suppl.313
https://doi.org/10.1200/jco.2023.41.4_suppl.313
Autor:
Christopher Duane Nevala-Plagemann, Jian Ying, Shashank Sama, Vaia Florou, Benjamin Haaland, Ignacio Garrido-Laguna
Publikováno v:
Journal of Clinical Oncology. 40:39-39
39 Background: For patients with refractory metastatic colorectal cancer (mCRC), both trifluridine/tipiracil (TAS-102) and regorafenib have received approval for use in the United States. The approvals of these agents were based on modest improvement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::555c642bbf62f3c4f4164deddc110fc3
https://doi.org/10.1200/jco.2022.40.4_suppl.039
https://doi.org/10.1200/jco.2022.40.4_suppl.039
Publikováno v:
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2019 (2019)
Case Reports in Oncological Medicine, Vol 2019 (2019)
Introduction. The management of patients with advanced malignancies is challenging, although recent advances with immunotherapy have shown better outcomes. Pembrolizumab has been associated with a variety of immune-related side effects, but the occur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75cf189eb78cd0fbb3b369d34ba7d01d
http://europepmc.org/articles/PMC6875007
http://europepmc.org/articles/PMC6875007